Mutant RAS Proteins Team Up for Oncogenicity

Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.

Jim Daley
Apr 1, 2018

DANGEROUS DIMERS: Linking mutant KRAS proteins with normal partners can make lung cancer (dark splotches) resistant to anticancer drugs. © iSTOCK.COM/OG PHOTO


C. Ambrogio et al., “KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS,” Cell, 172:857-68.e15, 2018.

Genes in the RAS family regulate cell growth and differentiation, and mutations can render them oncogenic. One such proto-oncogene, KRAS, frequently turns up in human cancers, including lung cancer, and is associated with resistance to chemotherapies including MEK inhibitors.

Some proteins encoded by RAS genes appear to function as dimers—linked pairs of identical molecules. Pasi Jänne, a medical oncologist at Dana-Farber Cancer Institute, used a fluorescence resonance energy transfer (FRET) assay to find that the KRAS protein does, too. They then fashioned a mutant KRAS that was dimerization-deficient.

Jänne and colleagues compared tumor...

Marie Evangelista, an oncology researcher at Genentech, notes that the strategy comes with its own hurdles. “It’s unclear whether there are going to be any small molecules that can target that interface” between KRAS monomers, she says. “We’re going to need to have a better understanding of how that interface is formed to find out if there are any opportunities to really go after it.”

Interested in reading more?

Magaizne Cover

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?